GSK has completed its acquisition of Nuvalent, a Boston-based clinical-stage biopharmaceutical company developing precisely targeted oncology treatments.
The deal adds three lung cancer assets, with zidesamtinib and neladalkib under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer, targeting decision dates later this year.
Both drugs carry FDA Breakthrough Therapy and Orphan Drug Designations, and GSK expects launches in 2026 with what it describes as multi-blockbuster potential.
The acquisition also brings NVL-330, a phase one asset for HER2-altered non-small cell lung cancer.
Chief executive Luke Miels said the completion "accelerates our entry into lung cancer with zidesamtinib and neladalkib and a platform for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III development."
GSK said the acquisition supports its stated ambition to expand oncology efforts beyond blood and women's cancers into lung and gastrointestinal cancers and other solid tumours, alongside priority programmes including antibody-drug conjugates Ris-Rez and Mo-Rez and the KIT inhibitor velzatinib.
The transaction follows the original agreement to acquire Nuvalent announced on 9 June.
